Topical Androgen Receptor Inhibitors Market Outlook:
Topical Androgen Receptor Inhibitors Market size was over USD 58.45 million in 2025 and is anticipated to cross USD 242.7 million by 2035, growing at more than 15.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of topical androgen receptor inhibitors is assessed at USD 66.5 million.
The need for potent topical androgen receptor inhibitors is driven by the increasing incidence of androgenetic alopecia and hirsutism, two disorders associated with androgen receptors. AGA is becoming more commonplace worldwide because of a combination of lifestyle, hormone fluctuations, and genetics. A greater number of patients are seeking effective treatments, such as topical androgen receptor inhibitors, as a result of this rising incidence. Excessive hair growth in women, frequently with a male pattern, is a symptom of hirsutism. Hormonal imbalances and conditions such as polycystic ovarian syndrome (PCOS) can aggravate hirsutism. Data from the World Health Organization (WHO) in June 2023 indicate that 8–13% of women of reproductive age have PCOS. Worldwide, up to 70% of afflicted women go undetected.
People are looking for ways to control their undesired hair growth as awareness of these conditions increases, which is driving up demand for topical androgen receptor inhibitors. The increasing prevalence of androgen-related conditions is a significant growth factor for the topical androgen receptor inhibitors market.
